CIBC Innovation Banking has provided growth capital financing to EnsoData, a Madison, Wisconsin-based healthcare technology company focused on artificial intelligence solutions for sleep medicine. The financing is intended to support EnsoData’s continued expansion as demand grows for more efficient, accessible, and scalable sleep diagnostics. While the companies did not disclose the size of the facility, the announcement highlights growing investor and lender interest in AI-enabled healthcare platforms with proven clinical use cases.
Growth Financing Supports Sleep Care Expansion
EnsoData develops software designed to help clinicians diagnose and manage sleep disorders more efficiently, particularly by reducing the manual workload associated with sleep study analysis. Its technology is used across the sleep care pathway, supporting providers from initial diagnosis through longer-term patient management. According to the company, its platform has supported care for more than 2.9 million patients to date, underscoring its growing role in the sleep medicine market.
AI-Powered Diagnostics at the Center of EnsoData’s Strategy
The company’s flagship product, EnsoHST, is a multi-night home sleep testing solution that combines a wearable device with a mobile application. The product is FDA-cleared and designed to deliver clinically reliable results while allowing patients to complete sleep testing outside of traditional lab settings. By automating analysis and reducing operational complexity, EnsoData aims to help clinicians increase capacity, shorten time to diagnosis, and improve patient outcomes.
Company Leaders Point to Broader Clinical Ambitions
Matt Dobereiner, chief financial officer of EnsoData, said the CIBC facility will help the company widen access to sleep care while also supporting further investment in AI-led diagnostic innovation. He noted that EnsoData’s work is not limited to current sleep medicine applications, with the company also exploring opportunities across additional clinical domains. That broader ambition positions the business within a larger healthcare trend in which AI tools are being used to address workflow bottlenecks, improve consistency, and expand access to care.
CIBC Backs Growth-Stage Healthcare Technology
CIBC Innovation Banking said it is pleased to support EnsoData’s growth and adoption among sleep medicine professionals. Andrew Schwartz, managing director at CIBC Innovation Banking, described EnsoData as operating at the intersection of artificial intelligence, machine learning, and improved access to patient care. The financing aligns with CIBC Innovation Banking’s broader focus on growth-stage technology and life sciences companies across North America and other global markets.
The growth capital facility gives EnsoData additional resources to expand its presence in sleep medicine and continue developing AI-powered diagnostic tools. For clinicians, the company’s technology aims to ease administrative and analytical burdens while supporting faster and more accessible testing for patients. For CIBC Innovation Banking, the deal reflects continued confidence in healthcare technology companies that combine regulatory clearance, clinical adoption, and scalable AI-driven software.